3 Research Led Drug Maker, Branded Formulations Company and Finished Dosage Generics Manufacturer Stocks With a Strong Future Roadmap: Glenmark Pharmaceuticals, JB Chemicals and Pharmaceuticals and Strides Pharma Science
- October 28, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Glenmark Pharmaceuticals, JB Chemicals and Pharmaceuticals and Strides Pharma Science: ROE of 17.1% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 14.3%. Prices as of 27 Oct 2026.
Quick Answer
The three innovation led and generic pharma stocks to watch are Glenmark Pharmaceuticals, JB Chemicals and Pharmaceuticals and Strides Pharma Science. Their return on equity ranges from 17.1% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 14.3%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while JB Chemicals and Pharmaceuticals has the fastest revenue growth at 14.3% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Innovation led and generic pharma stocks give investors a way to track businesses that sit close to everyday demand in India. Glenmark Pharmaceuticals, JB Chemicals and Pharmaceuticals and Strides Pharma Science cover a research led drug maker, a branded formulations company and a finished dosage generics manufacturer.
This list covers three innovation led and generic pharma stocks with complete current figures: Glenmark Pharmaceuticals, JB Chemicals and Pharmaceuticals and Strides Pharma Science. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Innovation Led and Generic Pharma Stocks?
Innovation led and generic pharma stocks are listed pharmaceutical companies that develop new drugs, sell branded medicines in India and make generic dosage forms for regulated markets. Their earnings depend on product launches, regulatory approvals, pricing and plant use.
Innovation Led and Generic Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | 2,265.7 | 60,103 | 33.4 | 35.7 | 28.1 | 0.06 |
| JB Chemicals and Pharmaceuticals | 2,408.9 | 38,731 | 54.6 | 35.8 | 17.1 | 0.00 |
| Strides Pharma Science | 1,093.3 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
On valuation, Glenmark Pharmaceuticals and Strides Pharma Science trade at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing innovation led and generic pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Innovation Led and Generic Pharma Stocks Have a Strong Roadmap in India?
Innovation led and generic pharma stocks have a strong roadmap in India because rising healthcare spending, new drug launches and demand for affordable generics keep widening the market for Indian pharma companies.
- Innovation. Research programmes can open new revenue streams.
- Branded medicines. Doctor-prescribed brands build repeat demand.
- Generic exports. Regulated markets widen the customer base.
Why Glenmark Pharmaceuticals Features Among These Innovation Led and Generic Pharma Stocks
Among the innovation led and generic pharma stocks on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.
In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%.
Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.
Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.
Why JB Chemicals and Pharmaceuticals Features Among These Innovation Led and Generic Pharma Stocks
Among the branded generic and finished dosage shares on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.
The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.
Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.
Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.
What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.
Why Strides Pharma Science Features Among These Innovation Led and Generic Pharma Stocks
Among the three companies on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%.
In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Glenmark Pharmaceuticals vs JB Chemicals and Pharmaceuticals vs Strides Pharma Science on Key Financials
The table below sets the three innovation led and generic pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | 12,472 | 17,443 | 8.7% | 1,362 | 7.8% |
| JB Chemicals and Pharmaceuticals | 2,463 | 4,208 | 14.3% | 709 | 16.9% |
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and JB Chemicals and Pharmaceuticals shows the fastest revenue growth with a 14.3% compound annual rate. A useful habit with innovation led and generic pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Innovation Led and Generic Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these innovation led and generic pharma stocks, the main points are: Long-term branded generic and finished dosage shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect supply.
- Pricing pressure. Generic prices can vary across markets.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter innovation led and generic pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Innovation Led and Generic Pharma Stocks
Innovation led and generic pharma stocks work best when investors track growth, valuation and return on equity side by side. Glenmark Pharmaceuticals, JB Chemicals and Pharmaceuticals and Strides Pharma Science each have a clear plan to expand. Based on the 27 October 2026 close, Glenmark Pharmaceuticals trades at Rs 2,265.7, JB Chemicals and Pharmaceuticals at Rs 2,408.9 and Strides Pharma Science at Rs 1,093.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these innovation led and generic pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track innovation led and generic pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are innovation led and generic pharma stocks?
Ans. Innovation led and generic pharma stocks are listed pharmaceutical companies that develop new drugs, sell branded medicines in India and make generic dosage forms for regulated markets. Their earnings depend on product launches, regulatory approvals, pricing and plant use. This list looks at three of them, Glenmark Pharmaceuticals, JB Chemicals and Pharmaceuticals and Strides Pharma Science, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which innovation led and generic pharma stocks are covered in this list?
Ans. This list covers Glenmark Pharmaceuticals, JB Chemicals and Pharmaceuticals and Strides Pharma Science. Based on the 27 October 2026 close, Glenmark Pharmaceuticals traded at Rs 2,265.7, JB Chemicals and Pharmaceuticals at Rs 2,408.9 and Strides Pharma Science at Rs 1,093.3. Their return on equity ranges from 17.1% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 14.3%.
Why do innovation led and generic pharma stocks have a strong future roadmap in India?
Ans. Innovation led and generic pharma stocks have a strong roadmap in India because rising healthcare spending, new drug launches and demand for affordable generics keep widening the market for Indian pharma companies. The main drivers are as follows. Innovation. Research programmes can open new revenue streams. Branded medicines. Doctor-prescribed brands build repeat demand. Generic exports. Regulated markets widen the customer base. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Glenmark Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
How has JB Chemicals and Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What risks should investors check before buying innovation led and generic pharma stocks?
Ans. Investors should check a few risks before buying innovation led and generic pharma stocks. Regulatory checks. Plant inspections can affect supply. Pricing pressure. Generic prices can vary across markets. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of innovation led and generic pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.